

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2018 (n/100,000 person years)

Belgium: Females 2018	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRi
C00 Lip	21	-	-	-	-	-	-	-	-	-	-	-	0.3	-	0.3	0.7	2.4	2.1	3.7	0.4	0.2	0.1	0.01
C01 Base of tongue	57	-	-	-	-	-	-	-	-	-	0.3	2.2	2.3	2.3	4.1	3.0	3.4	0.5	0.5	1.0	0.8	0.5	0.07
C02 Tongue	112	-	-	-	-	-	0.3	0.3	0.3	0.8	1.5	2.7	6.1	4.0	5.4	3.7	3.9	3.7	4.2	1.9	1.5	1.1	0.13
C03 Gum	43	-	-	0.3	-	0.3	-	-	-	-	-	-	0.5	1.1	2.9	1.1	2.9	4.8	3.7	0.7	0.4	0.3	0.03
C04 Floor of mouth	50	-	-	-	-	-	-	-	-	0.3	0.3	1.0	1.0	5.1	2.2	2.6	2.9	0.5	0.5	0.9	0.7	0.5	0.06
C05 Palate	43	-	-	-	0.3	0.3	-	-	-	-	0.8	0.5	0.8	2.8	2.5	2.6	1.0	1.1	1.8	0.7	0.5	0.4	0.05
C06 Mouth, NOS	50	-	-	-	-	-	-	-	-	-	-	1.0	0.5	2.0	2.5	2.2	3.9	4.8	2.8	0.9	0.5	0.3	0.04
C07 Parotid gland	37	-	-	0.3	0.3	0.3	0.5	0.3	0.3	0.6	0.5	0.5	0.5	0.8	0.6	2.6	2.4	1.1	1.4	0.6	0.5	0.4	0.04
C08 Salivary glands, NOS	6	-	-	-	-	-	-	-	-	-	-	-	-	0.3	0.6	0.7	0.5	-	-	0.1	0.1	0.0	0.01
C09 Tonsil	96	-	-	-	0.3	-	-	-	-	0.3	0.5	1.0	5.4	5.9	5.7	2.6	3.4	4.8	2.3	1.7	1.2	0.9	0.11
C10 Oropharynx	38	-	-	-	-	-	-	-	-	0.3	0.5	0.5	1.5	2.8	2.2	1.1	2.4	-	0.9	0.7	0.5	0.4	0.04
C11 Nasopharynx	21	-	-	-	-	-	0.3	0.6	0.5	0.3	0.3	1.2	-	0.6	0.3	0.7	0.5	1.1	0.5	0.4	0.3	0.2	0.02
C12 Pyriform sinus	24	-	-	-	-	-	-	-	-	-	-	0.2	1.0	1.4	1.3	1.8	1.0	0.5	0.9	0.4	0.3	0.2	0.03
C13 Hypopharynx	18	-	-	-	-	-	-	-	-	-	-	0.2	1.8	0.6	0.6	1.5	0.5	0.5	-	0.3	0.2	0.2	0.02
C14 Lip, oral cavity and pharynx, NOS	5	-	-	-	-	-	-	-	-	-	-	-	0.3	0.3	0.3	0.4	-	-	0.5	0.1	0.1	0.0	0.01
C15 Oesophagus	298	-	-	-	-	-	-	-	-	0.6	1.0	3.2	7.4	12.4	13.0	18.5	18.3	22.5	16.1	5.2	3.2	2.2	0.28
C16 Stomach	550	-	-	-	-	0.3	0.3	1.1	2.7	2.8	5.7	7.2	12.8	13.8	20.3	25.5	30.4	39.6	48.0	9.5	5.9	4.1	0.46
C17 Small intestine	152	-	-	-	-	-	-	0.6	0.8	1.9	1.5	2.0	2.8	6.2	5.7	9.2	7.2	9.1	8.3	2.6	1.8	1.3	0.15
C18 Colon	2,711	-	0.3	1.0	0.7	2.4	3.8	6.9	5.9	7.8	16.3	31.2	42.4	63.0	89.3	143.1	165.4	249.8	254.6	46.9	27.2	18.4	2.05
C19 Rectosigmoid junction	52	-	-	-	-	-	0.3	-	-	0.3	-	2.2	0.8	1.4	1.9	1.5	3.9	4.8	2.8	0.9	0.6	0.4	0.04
C20 Rectum	809	-	-	-	0.3	0.9	0.8	1.7	1.6	3.3	5.9	15.5	17.4	25.1	29.1	37.7	44.4	71.1	54.0	14.0	8.8	6.1	0.69
C21 Anus and anal canal	125	-	-	-	-	-	0.3	-	0.3	1.7	2.6	2.0	4.3	6.2	7.0	4.1	3.9	4.3	5.1	2.2	1.6	1.2	0.14
C22 Liver and intrahepatic bile ducts	322	1.0	-	0.3	-	-	-	0.3	0.8	1.9	2.8	3.7	6.1	9.9	13.9	20.3	20.7	25.7	14.8	5.6	3.6	2.6	0.31
C23 Gallbladder	74	-	-	-	-	-	-	-	-	0.3	0.3	0.2	1.3	0.8	4.1	5.2	6.3	6.4	5.1	1.3	0.7	0.5	0.06
C24 Biliary tract, NOS	168	-	-	-	-	-	-	-	0.3	0.3	0.8	0.7	3.8	3.1	6.0	8.9	13.0	16.6	15.2	2.9	1.6	1.0	0.12
C25 Pancreas	982	-	-	-	-	0.3	-	1.9	1.1	4.2	6.2	14.2	15.6	30.5	38.0	57.7	74.3	68.5	67.8	17.0	10.5	7.1	0.84
C26 Other ill-defined digestive organs	10	-	-	-	-	-	-	-	-	-	-	-	-	-	0.3	1.5	0.5	0.5	1.4	0.2	0.1	0.1	0.01
C30 Nasal cavity and middle ear	17	-	-	-	-	-	-	-	0.3	0.3	0.5	0.2	1.3	-	1.0	0.7	0.5	0.5	-	0.3	0.2	0.2	0.02
C31 Accessory sinuses	21	-	-	-	-	-	0.3	0.6	-	-	0.3	-	0.5	-	1.0	1.5	1.0	1.6	1.4	0.4	0.2	0.2	0.02
C32 Larynx	93	-	-	-	-	-	-	-	-	0.3	1.3	1.7	3.1	3.7	6.3	3.3	6.8	2.1	3.7	1.6	1.1	0.8	0.10
C33 Trachea	3	-	-	-	-	-	-	-	-	-	-	-	0.3	-	-	-	0.5	-	0.5	0.1	0.0	0.0	0.00
C34 Bronchus and lung	3,089	0.3	-	-	-	-	1.6	1.1	4.0	9.7	18.6	44.6	84.0	145.8	188.5	197.5	178.5	127.8	89.5	53.5	37.1	26.1	3.42
C37 Thymus	33	-	-	-	-	0.6	-	0.3	0.8	0.6	0.5	0.5	1.0	1.1	1.3	2.2	1.4	-	-	0.6	0.5	0.4	0.04
C38 Heart, mediastinum and pleura	5	-	-	-	-	0.3	-	-	-	-	-	-	0.3	-	-	0.4	-	-	0.9	0.1	0.1	0.0	0.00
C39 Respiratory system and intrathoracic organs, NOS	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.4	-	-	-	0.0	0.0	0.0	0.00
C40 Bone and articular cartilage of limbs	20	-	-	1.0	0.7	0.3	0.3	0.6	0.3	0.8	0.3	0.2	0.3	0.6	0.3	-	-	0.5	-	0.3	0.4	0.4	0.03
C41 Bone and articular cartilage, NOS	29	-	-	0.6	0.3	0.9	0.5	-	-	0.6	0.8	0.5	0.5	0.8	1.0	0.4	0.5	1.1	0.9	0.5	0.4	0.4	0.03
C43 Malignant melanoma of skin	1,949	-	-	-	2.0	10.6	12.1	23.1	30.5	41.5	49.8	61.9	48.8	46.0	58.3	61.4	66.1	61.5	54.4	33.7	28.1	21.8	2.21
C44 Malignant neoplasms of skin	3,502	-	0.3	-	-	0.3	0.3	2.2	3.2	6.4	14.2	21.5	33.7	55.9	85.5	153.1	240.7	351.9	527.6	60.6	29.8	18.7	1.87

Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2018 (n/100,000 person years)

Belgium: Females 2018	Tot	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CR	ESR	WSR	CRi
C45 Mesothelioma	62	-	-	-	-	-	-	-	-	-	0.8	0.7	1.0	2.3	1.9	3.0	5.8	4.3	4.6	1.1	0.7	0.4	0.05
C46 Kaposi's sarcoma	8	-	-	-	-	-	-	-	-	0.6	-	-	0.5	0.3	-	0.4	-	0.5	0.5	0.1	0.1	0.1	0.01
C47,C49 Soft tissues	153	2.6	0.9	0.3	1.0	0.3	0.5	0.8	0.3	1.4	2.6	2.5	3.3	5.6	4.1	7.0	6.3	7.0	6.9	2.6	2.1	1.8	0.17
C48 Retroperitoneum and peritoneum	46	0.3	-	-	0.3	0.3	-	-	0.8	0.6	0.3	1.0	0.5	0.3	1.3	2.6	3.4	3.7	2.3	0.8	0.6	0.4	0.04
C50 Breast	10,905	-	-	-	-	1.5	13.2	36.9	84.8	152.1	233.7	297.6	311.7	383.6	434.9	438.3	457.3	446.6	384.6	188.7	143.3	104.9	11.26
C51 Vulva	246	-	-	-	-	-	-	0.6	1.1	1.9	2.8	3.0	5.4	6.2	7.3	11.8	12.5	17.6	24.4	4.3	2.6	1.8	0.20
C52 Vagina	43	-	-	-	-	-	-	0.3	-	0.3	0.3	1.2	1.5	0.3	2.2	1.1	1.9	2.7	4.2	0.7	0.5	0.3	0.04
C53 Cervix uteri	634	-	-	-	-	0.6	4.0	9.9	13.1	19.1	22.0	17.2	19.2	16.4	20.0	9.2	16.9	12.8	13.4	11.0	9.7	7.6	0.75
C54 Corpus uteri	1,429	-	-	-	-	-	0.3	1.1	1.9	3.6	10.8	14.5	34.0	54.5	70.3	99.5	84.9	105.9	52.1	24.7	16.1	11.1	1.44
C55 Uterus	12	-	-	-	-	-	-	-	-	0.3	0.3	-	0.3	-	0.6	-	0.5	1.1	1.8	0.2	0.1	0.1	0.01
C56 Ovary	748	-	-	1.3	0.3	0.3	2.4	2.8	4.5	6.6	8.3	14.0	17.1	25.1	27.9	35.5	44.9	42.8	37.4	12.9	9.0	6.5	0.73
C57 Female genital organs, NOS	113	-	-	-	-	-	0.3	0.3	0.3	0.6	0.8	2.2	2.6	4.0	5.4	8.5	6.8	6.4	2.8	2.0	1.4	1.0	0.12
C58 Placenta	9	-	-	-	-	-	1.1	0.8	0.5	-	-	-	-	-	-	-	-	-	-	0.2	0.2	0.2	0.01
C64 Kidney	638	1.7	0.3	-	-	-	0.5	0.3	4.0	4.2	8.0	7.2	15.3	20.3	25.7	35.5	45.8	39.6	28.1	11.0	7.5	5.3	0.61
C65 Renal pelvis	88	-	-	-	-	-	-	-	-	-	-	0.2	1.8	2.5	3.2	5.2	4.3	11.2	7.8	1.5	0.8	0.5	0.06
C66 Ureter	57	-	-	-	-	-	-	-	-	-	-	0.2	0.5	0.8	1.9	4.1	3.9	8.0	5.1	1.0	0.5	0.3	0.04
C67 Bladder	524	-	-	-	-	-	-	0.3	0.3	1.7	1.3	3.0	8.2	12.7	16.5	25.9	40.5	58.3	49.3	9.1	4.9	3.2	0.35
C68 Urinary organs, NOS	9	-	-	-	-	-	-	-	-	-	-	-	0.3	-	0.3	0.7	0.5	0.5	1.4	0.2	0.1	0.0	0.01
C69 Eye and adnexa	69	1.7	0.3	-	0.3	-	-	-	1.1	0.3	0.8	3.2	1.8	3.1	1.9	1.5	1.9	3.2	1.4	1.2	1.0	0.9	0.08
C70 Meninges	9	-	-	-	-	-	-	-	0.3	-	0.3	0.2	-	0.3	-	-	0.5	2.1	-	0.2	0.1	0.1	0.01
C71 Brain	329	1.3	1.5	1.9	0.7	0.6	1.6	3.0	2.1	3.9	6.7	6.7	7.2	7.9	13.9	17.0	14.0	12.3	9.2	5.7	4.5	3.6	0.38
C72 Spinal cord, cranial nerves and CNS, NOS	19	0.7	0.3	0.3	-	-	0.3	0.3	0.3	0.6	-	0.2	0.8	-	0.6	0.4	1.0	0.5	-	0.3	0.3	0.3	0.02
C73 Thyroid gland	720	-	0.3	1.3	3.3	5.4	12.4	13.2	14.5	18.0	20.1	18.0	16.9	20.9	20.6	21.8	13.0	10.7	6.0	12.5	11.4	9.5	0.93
C74 Adrenal gland	43	1.0	0.3	-	-	-	0.5	0.3	0.5	1.4	0.8	0.7	1.0	1.1	1.0	1.8	1.4	2.1	-	0.7	0.7	0.6	0.05
C75 Endocrine glands, NOS	26	-	0.3	-	-	0.3	-	0.3	-	0.3	0.5	1.0	1.3	1.1	0.6	1.5	0.5	-	-	0.4	0.4	0.3	0.04
C81 Hodgkin lymphoma	162	-	-	2.2	4.2	4.5	4.6	2.8	4.5	1.1	2.6	2.2	2.3	4.0	3.8	3.3	4.8	1.1	1.8	2.8	2.7	2.6	0.21
C82-C86 Non-Hodgkin-lymphoma	912	0.7	0.6	0.6	1.6	3.9	3.2	3.3	3.5	4.4	10.3	12.0	14.6	26.6	33.9	50.7	64.2	61.0	48.4	15.8	10.6	7.7	0.85
C88 Malignant immunoproliferative diseases	154	-	-	-	-	-	-	0.6	0.3	1.4	1.5	2.2	3.3	3.1	6.7	8.9	10.6	7.5	12.0	2.7	1.7	1.2	0.14
C90 Multiple myeloma	442	-	-	-	-	-	-	-	0.8	1.7	2.6	5.5	6.6	12.4	20.9	24.4	33.3	38.5	26.7	7.6	4.6	3.1	0.37
C91 Lymphoid leukaemia	452	5.6	1.8	3.2	1.0	0.9	0.8	1.4	1.3	2.5	2.8	7.0	10.5	13.3	14.6	25.2	24.6	28.3	21.2	7.8	5.7	4.6	0.46
C92 Myeloid leukaemia	351	1.0	0.6	0.6	0.3	2.1	2.2	1.1	3.5	3.3	5.4	4.2	6.4	9.6	12.4	15.9	15.9	21.9	21.2	6.1	4.3	3.3	0.34
C93 Monocytic leukaemia	79	0.3	-	-	-	-	0.5	-	0.3	0.6	0.3	0.7	0.5	1.7	2.9	4.1	4.8	6.4	8.8	1.4	0.8	0.6	0.06
C94-C95 Leukaemia other	12	-	-	-	-	0.3	-	-	-	-	-	-	0.3	0.3	-	1.1	0.5	1.1	1.4	0.2	0.1	0.1	0.01
C96 Lymphoid, haematopoietic and related tissue, NOS	10	-	-	-	0.7	-	-	-	0.3	0.8	-	-	0.3	0.3	-	0.7	-	-	-	0.2	0.2	0.2	0.02
C76 Other and ill-defined sites	5	-	0.3	-	-	-	-	-	-	0.3	-	-	0.3	0.3	-	-	-	0.5	-	0.1	0.1	0.1	0.01
C80 Unknown primary site	367	-	-	-	-	0.3	-	0.3	0.5	2.8	3.6	2.2	4.9	10.2	12.0	16.3	22.2	36.4	36.4	6.4	3.6	2.4	0.27
MPN Myeloproliferative neoplasms	437	-	-	0.3	0.3	-	1.1	0.8	2.7	2.5	4.4	6.2	6.4	13.3	19.3	22.9	30.4	32.1	22.6	7.6	4.9	3.5	0.40
MDS Myelodysplastic syndromes	363	-	-	0.3	-	-	0.3	-	0.8	0.3	2.3	3.2	4.6	9.0	10.5	19.2	34.7	31.0	32.3	6.3	3.6	2.3	0.25
Total	36,321	18.2	8.3	16.0	18.9	39.3	71.5	122.5	202.3	326.3	491.0	665.2	823.1	1,129.9	1,402.2	1,706.6	1,929.3	2,157.5	2,071.5	628.6	432.8	311.6	29.68
Total excl. non-melanoma	32,819	18.2	8.0	16.0	18.9	39.0	71.2	120.3	199.1	319.9	476.8	643.8	789.4	1,073.9	1,316.7	1,553.5	1,688.7	1,805.6	1,544.0	568.0	403.0	292.8	28.34
Total excl. non-melanoma and MDS, MPN	32,019	18.2	8.0	15.4	18.6	39.0	69.9	119.5	195.6	317.2	470.1	634.3	778.4	1,051.6	1,286.9	1,511.3	1,623.5	1,742.4	1,489.1	554.1	394.5	287.0	27.87

CR: crude (all ages) incidence rate (n/100,000 person years)

ESR and WSR: age standardised incidence rate, using the European or World Standard Population (n/100,000 person years)

CRi: Cumulative Risk (0-74 years)